Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin detemir, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; glycerol; dibasic sodium phosphate dihydrate; metacresol; hydrochloric acid; zinc acetate; water for injections; sodium hydroxide; sodium chloride - treatment of diabetes mellitus. (see 'pharmacology' and 'clinical trials.')

Israel - anglès - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - solution for injection - pasireotide as diaspartate 0.3 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - anglès - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - solution for injection - pasireotide as diaspartate 0.6 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - anglès - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - solution for injection - pasireotide as diaspartate 0.9 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Singapur - anglès - HSA (Health Sciences Authority)

pharm-d singapore private limited - pasireotide diaspartate 0.37621mg eqv. pasireotide - injection, solution - 0.3mg - pasireotide diaspartate 0.37621mg eqv. pasireotide 0.3mg

Singapur - anglès - HSA (Health Sciences Authority)

pharm-d singapore private limited - pasireotide diaspartate 0.75242mg eqv. pasireotide - injection, solution - 0.6 mg - pasireotide diaspartate 0.75242mg eqv. pasireotide 0.6 mg

Singapur - anglès - HSA (Health Sciences Authority)

pharm-d singapore private limited - pasireotide diaspartate 1.12863mg eqv. pasireotide - injection, solution - 0.9 mg - pasireotide diaspartate 1.12863mg eqv. pasireotide 0.9 mg

Unió Europea - anglès - EMA (European Medicines Agency)

recordati rare diseases - pasireotide - acromegaly; pituitary acth hypersecretion - pituitary and hypothalamic hormones and analogues - signifor is indicated for the treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - pasireotide diaspartate - solution for injection - 300microgram/1ml

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - pasireotide diaspartate - solution for injection - 600microgram/1ml